TABLE 1

Effect of bFGF and PKC inhibitors on the BMD, BMC, and bone volume in tibia bFGF (300 ng/ml, 10 μl, once per day) and PKC inhibitor Ro 318220 (100 pmol), H7 (1 nmol), or GF109203X (100 pmol) were locally administered into tibia through the needle cannula in the proximal tibia for 1 week. Vehicle was injected into the contralateral side for comparison. Rats were sacrificed, and the tibiae were used for analysis of 7 days after the last injection. n = 8–12

	BMD	BMC	BV/TV
	g/cm^2/TD	g	%
Control	0.090 ± 0.002	0.081 ± 0.002	8.9 ± 0.6
bFGF	0.102 ± 0.004^a	0.111 ± 0.01^a	18.2 ± 1.8^a
H7	0.087 ± 0.004	0.073 ± 0.005	5.8 ± 0.4^a
Ro 318220	0.087 ± 0.005	0.073 ± 0.006	6.9 ± 0.7^a
GF109203X	0.086 ± 0.004	0.072 ± 0.004	5.9 ± 0.6^a
bFGF + H7	0.093 ± 0.004^b	0.085 ± 0.007^b	9.3 ± 0.8^b
bFGF + Ro318220	0.093 ± 0.006^b	0.091 ± 0.006^b	8.1 ± 1.2^b
bFGF + GF109203X	0.092 ± 0.005^b	0.087 ± 0.006^b	8.8 ± 0.8^b

BV/TV, bone volume/tissue volume.
↵ a P < 0.05: compared with control groups
↵ b P < 0.05: compared with bFGF-treated groups